Abstract
White adipose tissue (WAT) is a metabolically active organ that is adaptive and undergoes changes throughout
the human lifespan. While adipocyte number can increase via recruitment of precursors in the stromal vascular
fraction (SVF) of WAT to differentiate into adipocytes, the total number of adipocytes in WAT is set mainly
during adolescence, and thus changes in WAT mass, adiposity, mostly reflect alterations in lipid storage. In
obesity, WAT may become severely dysfunctional and does not expand properly to store the excess energy,
resulting in ectopic fat deposition and lipotoxicity in other tissues. Unhealthy expansion of WAT by adipocyte
hypertrophy (increasing cell size) may also result in deleterious effects, such as insulin resistance and type 2
diabetes. In addition, SVF populations may drastically change and be contributing factors towards disease
progression. Hence, maintaining white adipose tissue with balance between adipocyte hypertrophy and
hyperplasia (increasing cell number) is important for whole-body metabolism and energy balance. In general,
WAT is categorized as either subcutaneous (SAT) or visceral (VAT) adipose tissue. SAT provides insulation
and cushioning and serves as a long-term energy storage depot. VAT cushions and maintains distance
between organs and is critical for lipid storage during hyperphagia. While VAT is associated with pathological
conditions, such as insulin resistance and cardiovascular disease, SAT is protective against these diseases.
During aging, VAT tends to increase while SAT decreases significantly. VAT expansion occurs as lipid storage
is shifted from SAT to VAT and visceral adipocyte hypertrophy increases. However, the explanation behind the
decrease in metabolically protective SAT mass during aging has been more elusive. Although the
developmental origin and function of VAT and SAT are known to differ, in general, the proliferation and
differentiation capacities of adipose precursor cells (APCs) in each depot are believed to drastically decline
during aging. I have recently reported that aging-dependent regulatory cells (ARCs) emerge and accumulate
as a unique subpopulation of SAT during aging. ARCs arise from APCs but exhibit impaired differentiation
capacity and express high levels of proinflammatory cytokines.
By secreting cytokines, such as Ccl6, ARCs
inhibit the proliferation and differentiation of neighboring bona fide APCs. Thus, the emergence of ARCs is
responsible for the drastic decrease in adipose precursors and defects in adipogenesis, resulting in the loss of
SAT during aging. Interestingly, the transcription factor PU.1 is the driver for the development of ARCs in SAT
during aging. Though I have shown PU.1 to be responsible for the development of ARCs, the exact
mechanism by which PU.1 alters the transcriptome of ARCs is currently unknown. Therefore, the objective of
the proposed study will be to 1) identify the mechanism by which PU.1 alters gene expression in ARCs and to
2) characterize the role of PU.1 on SAT function in vivo.